Trial
NCT03333746
Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple Myeloma
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Yvonne Efebera
Collaborators
National Cancer Institute (NCI); American Cancer Society, Inc.; Bristol-Myers Squibb
Condition
Recurrent Plasma Cell Myeloma
Intervention
Laboratory Biomarker Analysis
Why stopped
Study was discontinued due to FDA recommendations of the potential toxicities of the combination of drugs.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-05-30